07/06/2024  17:36:00 Var. +0.025 Volume Denaro07/06/2024 Lettera07/06/2024 Capitalizzazione di mercato Dividend Y. Rapporto P/E
1.725EUR +1.47% 15,574
Fatturato: 26,834.815
-Quantità in denaro: - -Quantità in lettera: - 21.42 mill.EUR 30.12% 0.72

Descrizione business

NanoRepro AG is an innovative leader in the development, manufacturing and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use, in the domestic and international markets. Since October 2008, NanoRepro has been publicly listed with its headquarters located in Marburg, Germany. Its goal is to provide accuracy in self-diagnostics for rapid disease detection. Self-diagnostics is a fast growing market shaped by the ever-increasing health conscious of the population and healthcare spending. The rapid diagnostic tests offer significant advantages over all available competitive products due to the flexibility in product design, in-depth market understanding and best practices of just-in-time manufacturing. The company has currently around 25 rapid diagnostic tests within the portfolio addressing various healthcare needs (family planning, preventive healthcare, allergies, and infectious diseases).
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Lisa Jüngst
Consiglio di amministrazione
Stefan Pieh
Consiglio di sorveglianza
Dr. Olaf Stiller, Michael J. Tillmann, Clemens Jakopitsch, Dr. Bhuwnesh Agrawal, Hauke Heinz Hillmer, Rainer Barth
 

Dati aziendali

Name: NanoRepro AG
Indirizzo: Untergasse 8,D-35037 Marburg
Telefono: +49-6421-951449
Fax: +49-6421-951451
E-mail: info@nano.ag
Internet: www.nano.ag
Industria: -
Settore: -
Sub settore: -
Fine dell'anno finanziario: 31/12
Flottante libero: 88.00%
Data dell'IPO: -

Rapporti con gli investitori

Name: Lisa Jüngst
IR telefono: -
IR Fax: -
IR e-mail: juengst@nanorepro.com

Principali azionisti

Freefloat
 
88.00%
Management
 
12.00%